ImpediMed Presents at Bioshares Biotech Summit 2016
PR Newswire - Fri Jul 29, 11:07AM CDT
ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, announced that Managing Director and CEO, Richard Carreon, presented at the Bioshares Biotech Summit 2016 in Queenstown, New Zealand, on Friday, July 29, 2016.
IPD: 35.67 (+0.40)
ImpediMed and Mayo Clinic Sign Joint Development Agreement
PR Newswire - Thu Jul 28, 8:27AM CDT
ImpediMed Limited (ASX: IPD) announced today that it has entered into a three-year joint development agreement with Mayo Clinic to advance new solutions for its fluid status and body composition monitoring technology in additional disease indications.
IPD: 35.67 (+0.40)
Vanderbilt to Begin Testing Next Generation Device
PR Newswire - Mon Jul 18, 8:52AM CDT
ImpediMed Limited (ASX:IPD) announces that it is partnering with Vanderbilt University for a series of patient and clinician human factors testing for the company's next generation technology platform. Testing is expected to conclude by end of September 2016.
IPD: 35.67 (+0.40)
Medicare Proposes New Reimbursement Rates, L-Dex Increases
PR Newswire - Tue Jul 12, 10:20AM CDT
ImpediMed Limited (ASX:IPD) is pleased to announce today the Centers for Medicare and Medicaid Services (CMS) has published the proposed outpatient payment rates for CY2017. This includes code 93702 for the company's L-Dex® procedure for the assessment of lymphedema.
IPD: 35.67 (+0.40)
Australian Medical Technology Company Opens Minnesota Office
PR Newswire - Wed Jun 08, 10:00AM CDT
Australian-based medical technology company ImpediMed Limited (ASX: IPD) announced today the opening of a regional office in Bloomington, Minn., and the addition of two Minnesota medical technology veterans - Ann Holder and Jack Cosentino - to its executive leadership team.
MDT: 87.63 (+0.21), IPD: 35.67 (+0.40)
ImpediMed Signs Five Year, Multi-Location Clinical Trial Agreement with Mayo Clinic
PR Newswire - Tue May 31, 9:15AM CDT
ImpediMed Limited (ASX: IPD) announced today that it has entered into a five year master clinical trial agreement with Mayo Clinic to explore additional indications for its fluid status and body composition monitoring technology.
IPD: 35.67 (+0.40)
ImpediMed completes A$75 million Private Placement
PR Newswire - Tue Mar 22, 10:07AM CDT
ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status in patients, announced the completion of its recent capital raising activity, raising a total of A$75.1 million before costs.
IPD: 35.67 (+0.40)
ImpediMed Establishes Medical Advisory Board for Chronic Heart Failure
PR Newswire - Mon Jan 11, 11:30AM CST
ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status and body composition, announced today that it has entered into agreements to establish a Medical Advisory Board to advise the Company on the design of clinical trials for the use of bioimpedance spectroscopy (BIS) in fluid detection for chronic heart failure patients.
IPD: 35.67 (+0.40)
ImpediMed Announces U.S. Commercial Launch of L-Dex® System for Assessment of Lymphedema in Cancer Survivors
PR Newswire - Thu Jan 07, 12:51PM CST
ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status in patients, has announced the U.S. commercial launch of its L-Dex® system to aid in the clinical assessment of lymphedema.
IPD: 35.67 (+0.40)